HER2+ Breast Cancer Treatment Dynamics and Challenges
Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.
EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals
EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer
EP: 3.HER2+ Breast Cancer: Anthracycline Considerations
EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends
EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring
EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer
EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer
EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials
EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer
EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases
EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights
EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges
EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer
EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy and Rugo discuss the HER2CLIMB-02 trial, summarizing its key findings and considering its place in the treatment algorithm. The trial, conducted in a different era, focused on a second-line setting, comparing T-DM1 (trastuzumab emtansine) plus or minus tucatinib in patients with HER2-positive breast cancer. The results demonstrated a significant improvement in median progression-free survival, especially in the subset with brain metastases. The trial’s unique aspects include a diverse patient population with varying lines of prior therapy.
Isaacs emphasizes the importance of survival data and expresses a preference for the HER2CLIMB regimen due to the established phase 3 trial. Rugo adds insights about the trial’s context, highlighting the changing treatment landscape and the need for access to effective therapies globally.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
